Search results for "acetylcholinesterase"

showing 10 items of 86 documents

Use of atropine-treated Daphnia magna survival for detection of environmental contamination by acetylcholinesterase inhibitors.

2003

The toxicity of cholinesterase-inhibiting compounds (e.g., carbamates and organophosphates) is due to a decrease in acetylcholine metabolism, which results in a continuous stimulation of cholinergic receptors (muscarinic and nicotinic) that can be fatal. The goal of this study was to evaluate the protective effect of atropine (muscarinic receptor antagonist) against paraoxon-induced toxicity to Daphnia magna using its survival rate for the detection of environmental contamination by cholinesterase-inhibiting compounds. As expected, paraoxon was lethal to D. magna in a concentration-dependent manner. Noteworthy, the pretreatment of these organisms with atropine dramatically increased their s…

AtropineSurvivalHealth Toxicology and MutagenesisDaphnia magnaMuscarinic AntagonistsBiologyPharmacologyParaoxonToxicologychemistry.chemical_compoundMuscarinic acetylcholine receptormedicineAnimalsreproductive and urinary physiologyParaoxonfungiPublic Health Environmental and Occupational HealthGeneral Medicinebiology.organism_classificationPollutionAcetylcholinesteraseAtropineNicotinic agonistchemistryDaphniaToxicityCholinergicCholinesterase InhibitorsBiomarkersWater Pollutants Chemicalmedicine.drugEcotoxicology and environmental safety
researchProduct

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.

2001

BACKGROUND:Amyloid precursor protein (APP) forms with apparent molecular weights of 130, 110, and 106 kd are present in human platelets. It has been demonstrated that Alzheimer disease (AD) is specifically associated with a decreased APP forms ratio in platelets. OBJECTIVE:To investigate whether acetylcholinesterase (AChE) inhibitor treatment modifies the ratio of platelet APP forms in patients with AD. PATIENTS AND METHODS:From a large sample of patients with probable AD, 30 with mild to moderate AD were selected. Each patient underwent a clinical evaluation including the Mini-Mental State Examination (MMSE) and platelet APP forms analysis at baseline and after 30 days. During this interva…

Blood PlateletsMalemedicine.medical_specialtyIsoformmedicine.drug_classBlotting WesternAlzheimer disease; biomarker; platelet; Amyloid Precursor Protein; Isoformchemistry.chemical_compoundAmyloid beta-Protein PrecursorArts and Humanities (miscellaneous)PiperidinesDonepezil HydrochlorideInternal medicinemental disordersAmyloid precursor proteinMedicineHumansPlateletDonepezilLongitudinal StudiesDonepezilCholinesteraseAgedamyloid alzheimer diseaseplateletbiologybusiness.industryMiddle AgedAcetylcholinesteraseEndocrinologychemistryAcetylcholinesterase inhibitorEnzyme inhibitorIndansAmyloid Precursor Proteinbiology.proteinbiomarkerSettore MED/26 - NeurologiaFemaleNeurology (clinical)Cholinesterase InhibitorsAlzheimer diseasebusinessmedicine.drugFollow-Up Studies
researchProduct

Therapeutic properties of haemodialysis and blood exchange transfusion in organophosphate poisoning

1976

Human blood was contaminated with nitrostigmine, dimethoate and demeton-S-methyl sulfoxide. It was then dialysed, concentrations of organophosphates were determined and dialysance values calculated. The influence of blood exchange transfusion on poison elimination as well as on the cholinesterase activity of blood, brain and muscle was studied in rats poisoned with nitrostigmine. Haemodialysis was found to be quite an effective method for eliminating demeton-S-methyl sulfoxide and dimethoate, dialysance values of 52.98 ml/min and 59.07 ml/min being found for demeton-S-methyl sulfoxide and dimethoate respectively. Nitrostigmine could not be removed by haemodialysis. These findings suggest th…

Blood transfusionmedicine.medical_treatmentCritical Care and Intensive Care MedicineOrganophosphate poisoning03 medical and health scienceschemistry.chemical_compoundOrganophosphate PoisoningOrganophosphorus Compounds0302 clinical medicineRenal DialysisAnimalsMedicineBlood Transfusion030212 general & internal medicineCholinesteraseParathionbiologyHuman bloodbusiness.industryPoisoningBlood exchange transfusionGeneral Medicinemedicine.diseaseAcetylcholinesteraseRats3. Good healthParathionchemistrySulfoxidesAnesthesiaAcetylcholinesterasebiology.proteinbusinessDimethoate030217 neurology & neurosurgeryEuropean Journal of Intensive Care Medicine
researchProduct

Selective chromo-fluorogenic detection of DFP (a Sarin and Soman mimic) and DCNP (a Tabun mimic) with a unique probe based on a boron dipyrromethene …

2014

[EN] A novel colorimetric probe (P4) for the selective differential detection of DFP (a Sarin and Soman mimic) and DCNP (a Tabun mimic) was prepared. Probe P4 contains three reactive sites; i.e. (i) a nucleophilic phenol group able to undergo phosphorylation with nerve gases, (ii) a carbonyl group as a reactive site for cyanide; and (iii) a triisopropylsilyl (TIPS) protecting group that is known to react with fluoride. The reaction of P4 with DCNP in acetonitrile resulted in both the phosphorylation of the phenoxy group and the release of cyanide, which was able to react with the carbonyl group of P4 to produce a colour modulation from pink to orange. In contrast, phosphorylation of P4 with…

Boron CompoundsSarinORGANOPHOSPHATE PESTICIDESAcetonitrilesCyanideSomanColorSilica GelNERVE AGENTSCHEMICAL WARFARE AGENTSBiochemistryACETYLCHOLINESTERASESubstrate Specificitychemistry.chemical_compoundQUIMICA ORGANICALimit of DetectionSomanmedicineSENSORSNANOPARTICLESPhenolOrganic chemistryHumansChemical Warfare AgentsPhysical and Theoretical ChemistryPhosphorylationProtecting groupTabunNerve agentLANTHANIDE IONSReagent StripsRHODAMINE-BOrganic ChemistryQUIMICA INORGANICAMolecular MimicryMembranes ArtificialSarinOrganophosphatesFLUORESCENTchemistryMolecular ProbesSolventsColorimetryBODIPYFIELD-EFFECT TRANSISTORSNuclear chemistrymedicine.drugOrganicbiomolecular chemistry
researchProduct

Response and Recovery of Brain Acetylcholinesterase Activity in the European Eel,Anguilla anguilla,Exposed to Fenitrothion

1998

European eel (Anguilla anguilla) were exposed to sublethal fenitrothion concentrations in a continuous flow-through system for 4 days. Brain acetylcholinesterase (AChE) activity was evaluated after 2, 8, 12, 24, 32, 48, 56, 72, and 96 h pesticide exposure. Results indicated that AChE activity in eel brains decreased as the concentration of fenitrothion increased. The pesticide induced significant inhibitory effects on the AChE activity ofA. anguilla,ranging from >40% inhibition at a sublethal concentration of 0.02 ppm to >60% inhibition at a sublethal concentration of 0.04 ppm. Eel were exposed to both fenitrothion concentrations for 96 h and then allowed a period of recovery in pesticide-f…

Carboxylic Ester HydrolasesInsecticidesmedicine.medical_specialtyAchéHealth Toxicology and MutagenesisBiological effectFenitrothionchemistry.chemical_compoundInternal medicinemedicineAnimalsDose-Response Relationship DrugPublic Health Environmental and Occupational HealthBrainFenitrothionGeneral MedicinePesticideAnguillaPollutionAcetylcholinesteraselanguage.human_languageEuropeEndocrinologychemistryToxicityAcetylcholinesteraselanguageCholinesterase InhibitorsWater Pollutants ChemicalRecovery phaseEcotoxicology and Environmental Safety
researchProduct

Hsp60 is actively secreted by human tumor cells

2010

Background Hsp60, a Group I mitochondrial chaperonin, is classically considered an intracellular chaperone with residence in the mitochondria; nonetheless, in the last few years it has been found extracellularly as well as in the cell membrane. Important questions remain pertaining to extracellular Hsp60 such as how generalized is its occurrence outside cells, what are its extracellular functions and the translocation mechanisms that transport the chaperone outside of the cell. These questions are particularly relevant for cancer biology since it is believed that extracellular chaperones, like Hsp70, may play an active role in tumor growth and dissemination. Methodology/Principal Findings S…

Cell SurvivalBlotting WesternCellImmunology/Immunomodulationlcsh:MedicineApoptosisBiologyExosomesCell LineAmilorideCell membraneMicroscopy Electron TransmissionCell Line TumorNeoplasmsBiochemistry/Cell Signaling and Trafficking StructuresExtracellularmedicineHumansSecretionlcsh:ScienceMultidisciplinarySettore BIO/16 - Anatomia Umanabeta-Cyclodextrinslcsh:RChaperonin 60MicrovesiclesCell biologyPathology/PathophysiologyHSP60 Mitochondria Chaperonopatiesmedicine.anatomical_structureCell cultureCulture Media ConditionedCancer cellAcetylcholinesteraselcsh:QExtracellular SpaceK562 CellsIntracellularResearch Article
researchProduct

Enzyme-Controlled Nanodevice for Acetylcholine-Triggered Cargo Delivery Based on Janus Au–Mesoporous Silica Nanoparticles

2017

[EN] This work reports a new gated nanodevice for acetylcholine-triggered cargo delivery. We prepared and characterized Janus Au-mesoporous silica nanoparticles functionalized with acetylcholinesterase on the Au face and with supramolecular b-cyclodextrin: benzimidazole inclusion complexes as caps on the mesoporous silica face. The nanodevice is able to selectively deliver the cargo in the presence of acetylcholine via enzyme-mediated acetylcholine hydrolysis, locally lowering the pH and opening the supramolecular gate. Given the key role played by ACh and its relation with Parkinson's disease and other nervous system diseases, we believe that these findings could help design new therapeuti…

Cell SurvivalSupramolecular chemistryNanoparticleNanotechnologymacromolecular substances02 engineering and technology010402 general chemistry01 natural sciencesCatalysisQUIMICA ORGANICACIENCIA DE LOS MATERIALES E INGENIERIA METALURGICAQUIMICA ANALITICAmedicineOrganometallic CompoundsControlled releaseNanotechnologyHumansJanusNanodevicechemistry.chemical_classificationDrug CarriersChemistryHydrolysisQUIMICA INORGANICAOrganic Chemistrybeta-CyclodextrinsGeneral ChemistryMesoporous silicaHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEnzymes ImmobilizedSilicon DioxideControlled releaseMesoporous materialsAcetylcholine0104 chemical sciencesEnzymeDoxorubicinAcetylcholinesteraseNanoparticlesBenzimidazolesGold0210 nano-technologyPorosityAcetylcholinemedicine.drugHeLa Cells
researchProduct

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease

2000

The basic symptoms of Alzheimer's dementia, i.e., a loss in cognitive function, are due to impaired nicotinic cholinergic neurotransmission. To compensate for this impairment by drug treatment, blockers of the acetylcholine-degrading enzyme acetylcholinesterase are applied, even though this approach obviously is prone to many side-effects, including those of muscarinic nature. We have recently described a novel class of nicotinic acetylcholine receptor ligands which, similar to the action of benzodiazepines on GABA(A) receptors, allosterically potentiate submaximal nicotinic responses. The sensitizing effect is a consequence of facilitated channel opening in the presence of allosterically p…

Cholinergic AgentsReceptors NicotinicNeurotransmissionPharmacologyPC12 Cellschemistry.chemical_compoundCognitionAllosteric RegulationAlzheimer DiseaseMuscarinic acetylcholine receptormedicineAnimalsHumansLearningCells CulturedAcetylcholine receptorPharmacologyNeurotransmitter AgentsGalantamineAcetylcholinesteraseRatsNicotinic acetylcholine receptorNicotinic agonistchemistryCholinesterase InhibitorsAlpha-4 beta-2 nicotinic receptorNeuroscienceAcetylcholinemedicine.drugEuropean Journal of Pharmacology
researchProduct

Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet.

2009

In this study the development of a procedure based on capillary electrophoresis after enzymatic reaction at capillary inlet methodology for the screening and in vitro evaluation of the biological activity of acetylcholinesterase (AChE) inhibitors is presented. The progress of the enzymatic reaction of the hydrolysis of acetylthiocholine at pH 8 in the presence of AChE and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh). In the method employed the capillary was first filled with 30 mM borate-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) AChE solution, (iii) substrate solution with or without inhibitor,…

ChromatographyTime FactorsbiologyHydrolysisSubstrate (chemistry)Electrophoresis CapillaryFiltration and SeparationEdrophoniumAcetylcholinesteraseAnalytical ChemistryEnzyme Activationchemistry.chemical_compoundKineticsThiocholineCapillary electrophoresisNon-competitive inhibitionchemistryEnzyme inhibitorAcetylthiocholinemedicinebiology.proteinAcetylcholinesteraseCholinesterase InhibitorsSoftwaremedicine.drugJournal of separation science
researchProduct

Pharmacokinetic rationale for switching from donepezil to galantamine.

2001

Galantamine, the most recently approved acetylcholinesterase inhibitor (AChEI) for use in the United States, has allosteric modulating activity at nicotinic receptors and inhibits acetylcholinesterase. This dual mechanism of action may make galantamine an attractive option for patients with Alzheimer's disease who have not benefited from their current therapy; thus, methods for switching patients from donepezil or rivastigmine to galantamine are needed. Protocols for switching patients from one AChEI to another must consider both the time required for washout of the first drug and the rate of dose escalation of the second drug. Both issues depend on the pharmacodynamics, pharmacokinetics, a…

Drugmedicine.drug_classmedia_common.quotation_subjectPharmacologyModels Biologicalchemistry.chemical_compoundPharmacokineticsPiperidinesAlzheimer DiseaseGalantamineMedicineHumansPharmacology (medical)DonepezilDonepezilmedia_commonAgedPharmacologyRivastigminebusiness.industryGalantamineAcetylcholinesterasechemistryAcetylcholinesterase inhibitorPharmacodynamicsIndansCholinesterase Inhibitorsbusinessmedicine.drugClinical therapeutics
researchProduct